Quintiles Establishes Bioanalytical Laboratory in the Netherlands
Oss facility to provide additional depth and scale to existing laboratory capabilities
Quintiles, a North Carolina-based provider of biopharmaceutical development and commercial outsourcing services has announced the expansion of its bioanalytical laboratory services with the establishment of a GLP-compliant bioanalytical liquid chromatography-mass spectrometry (LC-MS) laboratory in Oss, Netherlands. The laboratory will have extensive bioanalytical testing capabilities and will provide a European facility for Quintiles customers to conduct pharmacokinetics studies.
“Adding this capability in Europe is a key step for our bioanalytical business and supports the strategy to increase our participation in the substantial European bioanalytical market,” said Costa Panagos, senior vice president and global head of Global Central Laboratories at Quintiles. “This is an exciting milestone for Quintiles and specifically our laboratory business as we expand our capabilities while continuing to provide the value and high-quality service our customers require.”
As part of Quintiles’ bioanalytical and ADME laboratory services group, the Oss lab would become part of the recently announced clinical trials laboratory services joint venture with New Jersey-based Quest Diagnostics. That transaction, which remains subject to regulatory approval and customary closing conditions, is anticipated to close in the third quarter of 2015.
“The Oss laboratory will further enhance the scale, clinical trial expertise and diverse therapeutic experience that will be a cornerstone of the proposed joint venture with Quest Diagnostics,” said Panagos. “The addition of the Oss laboratory is integral to the continued evolution of our laboratory business, and we’re excited about the benefits it can provide as part of a globally scaled and agile business for our customers today as well as in the future.”
Source: Quintiles press release4 May 2015